Acute Myeloid Leukaemia Therapeutics Market to Reach USD 9.12 Billion by 2030 as Targeted and Personalized Treatments Advance

Acute Myeloid Leukaemia Therapeutics Market Overview

The global Acute Myeloid Leukaemia Therapeutics Market was valued at USD 3.8 billion in 2023 and is projected to reach approximately USD 9.12 billion by 2030, expanding at a CAGR of 12.15% during 2024–2030, according to Maximize Market Research. The market is experiencing strong expansion as pharmaceutical companies and research institutions accelerate the development of targeted therapies, immunotherapies, and personalized treatment approaches. Rising AML incidence, advances in medical technology, molecular diagnostics, genetic profiling, and growing research and development expenditure are major contributors to market growth. AML's complex and heterogeneous nature is also encouraging companies to identify molecular abnormalities and develop therapies designed for specific patient populations. Strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are further supporting clinical development and commercialization opportunities. However, high treatment-development costs, drug resistance, regulatory requirements, clinical-trial complexity, and patient-access challenges remain important market constraints.

* Explore Investment Opportunities: https://www.maximizemarketresearch.com/request-sample/213386/

U.S. Market Trends and Investment

The United States remains a major center for AML therapeutic innovation, supported by advanced healthcare infrastructure, pharmaceutical R&D capabilities, and an active regulatory pathway for novel therapies. In 2025, the U.S. AML treatment landscape recorded several important regulatory developments. The FDA approved treosulfan with fludarabine in January 2025 as a preparative regimen for allogeneic hematopoietic stem-cell transplantation in adults and pediatric patients with AML or myelodysplastic syndrome. The FDA subsequently approved revumenib in October 2025 for relapsed or refractory AML with a susceptible NPM1 mutation and ziftomenib in November 2025 for adults with relapsed or refractory AML carrying a susceptible NPM1 mutation. These approvals demonstrate the increasing importance of mutation-directed and precision therapies in the U.S. market.

Hypomethylating Agents Hold a Significant Market Position

By treatment class, Hypomethylating Agents hold a significant market share in the global AML therapeutics market, according to MMR. Drugs such as azacitidine and decitabine are widely used in AML treatment and represent an established therapeutic approach, particularly as the market moves toward treatment strategies tailored to patient characteristics. The segment benefits from continued clinical research and the development of combination approaches intended to improve treatment outcomes. At the same time, targeted therapies are emerging as a prominent segment because they can address specific genetic mutations and molecular abnormalities associated with AML. The continued development of kinase inhibitors and other precision medicines is expected to create new opportunities across the treatment landscape.

Acute Myeloid Leukaemia Therapeutics Market,Key Players:
1. Pfizer Inc.
2. Novartis AG
3. Celgene Corporation (Acquired by Bristol Myers Squibb)
4. Astellas Pharma Inc.
5. Daiichi Sankyo Company, Limited
6. Jazz Pharmaceuticals
7. AbbVie Inc.
8. Boehringer Ingelheim International GmbH
9. Johnson & Johnson
10. Gilead Sciences, Inc.
11. Amgen Inc.
12. Takeda Pharmaceutical Company Limited
13. Merck & Co., Inc.
14. Sunesis Pharmaceuticals, Inc.
15. Agios Pharmaceuticals, Inc.

Competitive Landscape

MMR identifies Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., and Daiichi Sankyo Company, Limited among the leading companies in the AML therapeutics market. MMR does not publish individual market-share percentages for these companies, so specific percentage shares have not been assigned.

Pfizer Inc. maintains an AML presence through MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate targeting CD33-positive AML. The company's approach illustrates the continued role of targeted biologic therapies alongside conventional chemotherapy.

Novartis AG remains a major global pharmaceutical company identified by MMR, with its broader oncology research capabilities contributing to the competitive environment for innovative hematologic cancer treatments.

Celgene Corporation, which was acquired by Bristol Myers Squibb, remains included in MMR's company list. BMS continued to highlight AML as an important hematologic malignancy area in 2025, reflecting the industry's focus on improving treatment outcomes and addressing unmet needs.

Astellas Pharma Inc. continued advancing its AML franchise around XOSPATA (gilteritinib). In 2025, Astellas presented new data covering relapsed or refractory, newly diagnosed, and post-transplant FLT3-mutated AML, including research into treatment sequencing and combination strategies.

Daiichi Sankyo Company, Limited has an established AML portfolio through VANFLYTA (quizartinib), a FLT3 inhibitor used in newly diagnosed FLT3-ITD-positive AML in combination with chemotherapy and as maintenance therapy following consolidation.

Regional Analysis

USA: North America dominates the global AML therapeutics market, with the United States benefiting from leading pharmaceutical companies, advanced healthcare infrastructure, extensive clinical research, and strong adoption of innovative therapies.

UK: The UK contributes to European market growth through specialized hematology services, clinical research capabilities, and access to innovative cancer medicines.

Germany: Germany's advanced healthcare infrastructure and strong pharmaceutical and clinical-research ecosystem support demand for AML therapies. Treosulfan's 2025 FDA approval also included clinical evidence from European sites, including Germany.

France: France remains an important European market because of its established oncology treatment infrastructure and participation in international AML clinical research.

Japan: Japan has a significant role in AML innovation, particularly through companies such as Astellas and Daiichi Sankyo. XOSPATA and VANFLYTA are established examples of mutation-directed AML therapies available in the Japanese market.

China: China's expanding healthcare infrastructure, increasing oncology-treatment demand, and growing pharmaceutical R&D capabilities provide opportunities for long-term AML therapeutics growth.

Pupillometer Market https://www.maximizemarketresearch.com/market-report/pupillometer-market/213391/

Metaverse in Healthcare Market https://www.maximizemarketresearch.com/market-report/metaverse-in-healthcare-market/213965/

Conclusion

The Acute Myeloid Leukaemia Therapeutics Market is entering a high-growth phase as precision medicine, molecular diagnostics, targeted therapies, and innovative treatment combinations reshape AML management. The market's projected rise from USD 3.8 billion in 2023 to USD 9.12 billion by 2030 highlights substantial commercial and therapeutic opportunities. The strongest growth opportunity lies in developing therapies that target specific genetic and molecular drivers while improving treatment outcomes and addressing drug resistance. Continued regulatory approvals, clinical research, strategic collaborations, and personalized treatment approaches are expected to remain the primary forces shaping the market through 2030.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? sales@maximizemarketresearch.com